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ABSTRACT
Extracellular vesicles (EVs) aremediators of intercellular communication under both
healthy and pathological conditions, including the induction of pro-metastatic traits,
but it is not yet known how andwhere functional cargoes of EVs are delivered to their
targets in host cell compartments. We have described that after endocytosis, EVs
reach Rab7+ late endosomes and a fraction of these enter the nucleoplasmic reticu-
lum and transport EV biomaterials to the host cell nucleoplasm. Their entry therein
and docking to outer nuclear membrane occur through a tripartite complex formed
by the proteins VAP-A, ORP3 and Rab7 (VOR complex). Here, we report that the
antifungal compound itraconazole (ICZ), but not its main metabolite hydroxy-ICZ
or ketoconazole, disrupts the binding of Rab7 to ORP3–VAP-A complexes, leading
to inhibition of EV-mediated pro-metastatic morphological changes including cell
migration behaviour of colon cancer cells. With novel, smaller chemical drugs, inhi-
bition of the VOR complex was maintained, although the ICZ moieties responsible
for antifungal activity and interference with intracellular cholesterol distribution
were removed. Knowing that cancer cells hijack their microenvironment and that
EVs derived from them determine the pre-metastatic niche, small-sized inhibitors of
nuclear transfer of EV cargo into host cells could find cancer therapeutic applications,
particularly in combination with direct targeting of cancer cells.
KEYWORDS
cancer, endosome, exosome, intercellular communication, metastasis, micro-vesicle, nucleoplasmic
reticulum
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2021 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles
J Extracell Vesicles. 2021;10:e12132. wileyonlinelibrary.com/journal/jev2  of 
https://doi.org/10.1002/jev2.12132
 of  SANTOS et al.
 INTRODUCTION
Extracellular vesicles (EVs), including exosomes, microvesicles and other types of membrane particles act as mediators of inter-
cellular communication in tissues and organs under healthy and pathological conditions (Maas et al., 2017; Mathieu et al., 2019;
Raposo & Stoorvogel, 2013). Their role in modulation of immune responses, cell differentiation, and epithelial-mesenchymal
transition has been demonstrated. In cancer, their dysregulated secretion and altered cargoes (i.e., proteins, lipids and nucleic
acids) can promote tumour growth and lead tometastasis (Abdouh et al., 2017; Hoshino et al., 2015; Peinado et al., 2012), suggest-
ing that targeting EVs may prevent metastasis. However, our knowledge about EV cargos’ subcellular/molecular sites of action
in recipient cells is still fragmented. This is specifically true for proteins and nucleic acids associated with EVs that shuttle to the
nucleus of host cells (Santos et al., 2018).
Upon the cellular internalization of EVs by various endocytosis mechanisms (reviewed in Ref. [Corbeil et al., 2020]), the
fusion of endocytosed EVs with late endosome membrane and/or the breakdown of the latter could result in exposure of EVs
and/or their cargo to cellular cytosol (Joshi et al., 2020). The transfer of EV contents through endosomal compartment to the
endoplasmic reticulum (ER) has been proposed (Heusermann et al., 2016). Recently, we described a novel intracellular pathway
whereby EV-containing late endosomes enter in the nucleoplasmic reticulum through type II nuclear envelope invaginations
(NEI) and transfer EV cargoes into the nucleoplasm of recipient cells (Rappa et al., 2017). A tripartite protein complex named
VOR, containing ER-associated, vesicle-associated membrane protein (VAMP)-associated protein A (VAP-A), oxysterol-
binding protein (OSBP)-related protein-3 (ORP3) and late endosome-associated small GTPase Rab7 orchestrates entry and/or
docking of EV-containing late endosomes into NEI (Santos et al., 2018). Silencing VAP-A or ORP3 abrogated the localization
of Rab7+ late endosomes in NEI, and the subsequent nuclear transport of endocytosed EV-derived components (Santos et al.,
2018).
One VOR complex protein, namely ORP3, drew our attention as a potential therapeutic target because other members of
the OSBP family, regulate the lipid exchange, notably sterols found at membrane contact sites between organelles (Eden, 2016;
Olkkonen, 2015;Weber-Boyvat et al., 2015). OSBP proteins contain a highly conserved C-terminal OSBP-related domain (ORD),
whose hydrophobic pocket binds a single sterol, notably cholesterol and 25-hydroxycholesterol (25-HC) (Raychaudhuri & Prinz,
2010; Suchanek et al., 2007). OSBP-related proteins are involved in diverse functions ranging from lipid sensing and trafficking
to sterol homeostasis and cell signalling. ORP3 and VAP-A, an integral type II membrane protein, reportedly establish a contact
zone between ER and plasma membrane and regulate the activity of GTPase R-Ras (Lehto et al., 2005; Olkkonen, 2015; Weber-
Boyvat et al., 2015). The interaction of ORP3 and VAP-A occurs via two specific sequence motifs formed by two phenylalanines
in an acidic tract (FFAT) (Loewen et al., 2003; Olkkonen, 2015; Weber-Boyvat et al., 2015). A pleckstrin homology (PH) domain
mediates ORP3 interaction with phosphoinositides in non-ER organelles (Olkkonen, 2015), potentially including late endosomes
(Santos et al., 2018). Unlike theOSBP-related protein 1L (ORP1L), ORP3 does not contain an ankyrin repeat domain thatmediates
the Rab7 interaction at the contact zone of the ER-late endosome (Olkkonen, 2015; Rocha et al., 2009). The question of whether
the R-Ras-binding site of ORP3 is involved in the Rab7 interaction is open.
In search for drugs that could inhibit ORP3 function as component of theVOR complex, we came acrossORPphilinmolecules,
such as anti-proliferative natural product OSW-1 (Burgett et al., 2011) and the FDA-approved antifungal azole itraconazole (ICZ).
Through the inhibition of lanosterol 14α-demethylase, ICZ has clinically efficacious antifungal activity (Georgopapadakou &
Walsh, 1996). Also, ICZ has been shown to interfere with intracellular trafficking of cholesterol, resulting in abnormal accumu-
lation of cholesterol in the endosomal/lysosomal compartments (Liu et al., 2014; Trinh et al., 2017; Xu et al., 2010). An inhibitory
activity of ICZ on enterovirus and hepatitis C virus replication has been attributed to OSBP and ORP4 inhibition (Strating et al.,
2015). Its five ring-backbone structure and the sec-butyl chain are important for antiviral activity, whereas the triazole moiety,
which is critical for the antifungal activity (Bauer et al., 2018), is not. For cancer treatment, ICZ has been repurposed because of
its effect on the Hedgehog signalling pathway and angiogenesis (Pounds et al., 2017).
Here, we report that ICZ disrupts the VOR complex and inhibits EV-mediated pro-metastatic morphological transformation
and migratory properties of colon cancer cells. These effects do not require the ICZ moieties responsible for antifungal activity
or interference with intracellular cholesterol distribution, suggesting a novel mechanism of ICZ action. Altogether, we provide
evidence that the VOR complex (and its pathway) is a novel drug target to impair the intercellular communication in the cancer




2-(1-methyl-propyl)-3H-1,2,4-triazol-3-one; MW: 705.64) and ketoconazole were purchased from Sigma-Aldrich (catalogue
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numbers #I6657 and #K1003, respectively, St-Louis, MO, USA), while OSW-1 ((3β,16β)-3,17-dihydroxy-22-oxocholest-
5-en-16-yl-2-O-acetyl-3-O-[2-O-(4-methoxybenzoyl)-β-D-xylopyranosyl]-α-L-arabinopyranoside) was from Alfa Chemistry
(#ACM145075816, Ronkonkoma,NY,USA). The hydroxy-ICZ (H-ICZ), thapsigargin, imipramine and 25-HCwere all purchased
from Cayman Chemical (#22576, #10522, #15890 and #11097, respectively, Ann Arbor, MI, USA). Stock solutions were prepared
at 10mM in dimethyl sulfoxide (DMSO) (VWR International, Radnor, PA, USA) for ICZ, H-ICZ, ketoconazole and thapsigargin;
100 mM for imipramine; 20 mM for 25-HC; and 1 mM for OSW-1. Filipin complex from Streptomyces filipinensis was obtained
from Sigma-Aldrich (#F9765), and the stock solution prepared at 25 mg/ml in DMSO. λ-phosphatase was also purchased from
Sigma-Aldrich (#P9614) at a stock solution of 400,000 units (U) per ml.
. Synthesis of PRR and PRR compounds
All materials and solvents were purchased from commercial sources and used without further purification. All melting points
were obtained on a Büchi-Tottoly capillary apparatus (Büchi, Cornaredo, Italy) and have not been corrected. IR spectra were
determined in bromoform with a Shimadzu FT/IR 8400S spectrophotometer (Shimadzu Corporation, Milan, Italy). 1H spectra
were measured at 50.0MHz in DMSO-d6 solution, using a Bruker Avance II series 200MHz spectrometer (Bruker, Milan, Italy).
Column chromatography was performed with Merck silica gel 230–400 mesh ASTM or with a Büchi Sepacor chromatography
module (prepacked cartridge system). Elemental analyses (C, H, N) were within± 0.4% of theoretical values andwere performed
with a VARIO EL III elemental analyser (Elementar, Langenselbold, Germany). Purity of all the tested compounds was greater
than 95%, determined by HPLC (Agilent 1100 Series).
For the synthesis of 4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (PRR846), triethyl orthoformate (17.51 mmol,
2.9 ml), p-toluene sulphonic acid (1.5 mmol, 295 mg) and methyl carbazate (17.51 mmol, 1.6 g), were added to a solution of
4-chloroaniline (11.75 mmol, 1.5 g) in 100 ml methanol under nitrogen. The resulting reaction mixture was heated under reflux
for 3 h. Once cooled at 20◦C a solution of sodiummethoxide in methanol, prepared by addition of sodium (17.51 mmol, 403 mg)
to methanol (30 ml), was added to the mixture that was heated under reflux for two additional hours. The solvent was removed
at reduced pressure and crushed ice was added to the reaction crude material. The resulting white precipitate was filtered off and
recrystallized from methanol to afford the pure compound. Yield: 99%, white solid; mp: 101–102◦C; IR: 3122 (NH), 1714 (CO)
cm−1; 1H NMR (200 MHz, DMSO- d6) δ: 7.55-7.61 (2H, m, ArH), 7.72-7.79 (2H, m, ArH), 8.42 (1H, s, H-3), 12.02 (1H, s, NH);
anal. calculated for C8H6ClN3O (MW: 195.61): C, 49.12; H, 3.09; N, 21.48%. Found: C, 49.36; H, 2.95; N, 21.60%.
The synthesis of 2-(butan-2-yl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (PRR851) was performed from the
compound PRR846. To a PRR846 solution (4.1 mmol, 0.8 g) in DMSO (10 ml), Na2CO3 (8.2 mmol, 869 mg), 18-crown-6
(4.1 mmol, 1.08 g) and 2-bromobutane (5.33 mmol, 0.6 ml) were added. The reaction mixture was heated at 60◦C for 8 h. Once
cooled, distilled water was added and the mixture extracted with ethyl acetate (3 × 100 ml). The organic layers were dried over
anhydrous Na2SO4, filtered and evaporated in vacuo. The crudematerial was purified by silica gel column chromatography using
dichloromethane: ethyl acetate, 9:1 as eluent. Yield: 80%, white solid; mp: 102–103◦C; IR: 1689 (CO) cm−1; 1H NMR (200 MHz,
DMSO- d6) δ: 0.79 (3H, t, J= 7.4 Hz, CH3), 1.29 (3H, d, J= 6.7 Hz, CH3), 1.61-1.81 (2H,m, CH2), 4.08-4.18 (1H, m, CH), 7.54-7.60
(2H, m, ArH), 7.74-7.86 (2H, m, ArH), 8.51 (1H, s, H-3); anal. calculated for C12H14ClN3O (MW: 251.71): C, 57.26; H, 5.61; N,
16.69%. Found: C, 57.01; H, 5.81; N, 16.48%.
. Synthesis of fluorescent PRR compound
The synthesis of 2-ethyl-4-[4-(7-nitro-benzo[1,2,5]oxadiazol-4-ylamino)-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one (PRR898)
was performed from the compound 4-(4-amino-phenyl)-2-ethyl-2,4-dihydro-[1,2,4]triazol-3-one in which the fluorescent 7-
nitrobenzofurazan group was linked, employing the same synthetic procedure as previously reported (Barresi et al., 2018).
. Molecular modelling
The primary sequence of the humanORP3 protein was retrieved fromUniprot (entry: Q9H4L5, OSBL3_HUMAN) andwas sub-
mitted to the online Swiss-Model server to generate the corresponding homologymodel. Among the proposed possible templates,
the ORP3 protein was modelled by using the recently resolved ORP1 in complex with cholesterol (PDB Id: 5ZM5) (Dong et al.,
2019) chosen due to its sequence identity equal to 43.4% and the coverage, which allows the oxysterol binding domain of ORP3
to be completely modelled (Lehto et al., 2001). The generated model was then completed by adding the missing hydrogen atoms,
and the structure underwent energy minimization using nanoscale molecular dynamics Namd2 software (Acun et al., 2018) by
keeping fixed the backbone atoms to retain the predicted folding. The structure of the simulated ligands was optimized by the
PM7 semi-empirical method (Stewart, 2013). The ORP3 binding cavity was defined by superimposing the homology model with
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the experimental template. In this way, the corresponding position of the cholesterol within the ORP3 model was derived, thus
allowing a precise definition of the binding pocket to be used in the following docking simulations. In detail, docking simulations
were performed using the docking software PLANTS (Korb et al., 2009), focusing the search within an 8 Å radius sphere around
the so derived cholesterol position; for each ligand/drug 10 possible configurations were generated and ranked by the ChemPLP
scoring function with speed equal to one. The generated complexes were finally minimized by keeping fixed the atoms outside
an 8 Å radius sphere around the bound ligand and rescored by using ReScore+ tools (Vistoli et al., 2017).
The multiple sequence alignment of the ORD domain for seven ORP isoforms plus human OSBP was computed using Clustal
X (Larkin et al., 2007). Emphasis was placed on the main residues involved in PRR851 binding.
. Antibodies
The primary and secondary antibodies (Ab) used in this study, their working concentrations and validation are described in
Tables S1 and S2, respectively.
. Cell culture
All cells used in this study and their validation are described in Table S3. Human HeLa (ATCC®CCL-2TM), fibroblast BJ
(ATCC®CRL-2522TM), SW480 (CCL-228TM) and SW620 cells (CCL-227TM) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). FEMX-I cells were originally derived from a lymph node metastasis of a patient with
malignant melanoma and found to be highly metastatic in immunodeficient mice (Fodstad et al., 1988; Rappa et al., 2008) and
wild type for BRAF, PTEN and NRAS (Rappa et al., 2017). FEMX-I cells were authenticated by morphology and proteomics
(Rappa et al., 2013a). FEMX-I, SW480 and SW620 cells were cultured in RPMI-1640 medium (#10-041-CV, Corning Inc., NY,
USA), while HeLa and fibroblast BJ cells were kept in DMEM (#11995065, Thermo Fisher Scientific, Waltham, MA, USA).
Human primary bone marrow-derived mesenchymal stromal cells (MSCs) were originally acquired from D. J. Prockop (Texas
A&M University) and prepared under a protocol approved by the Texas A&M Institutional Review Board. Cells were cultured
in MEMα (#10-022-CV, Corning Inc.) and were used between passages three and five (Larson et al., 2008). All cell culture media
were supplemented with 10% fetal bovine serum (FBS, #26140079), 2 mM L-glutamine (#25030081), 100 U/ml penicillin and
100 μg/ml streptomycin (#15140122), all from Thermo Fisher Scientific. Cells were incubated at 37◦C in a 5% CO2 humidified
incubator. Cells were regularly verified for absence of mycoplasma contamination by either their staining with 4′,6-diamidino-
2-phenylindole (DAPI; #D9542, Sigma-Aldrich) and visualization under a fluorescent microscope or polymerase chain
reaction using the MycoSEQMycoplasma Detection Kit (#4460626, Thermo Fisher Scientific), according to the manufacturer’s
protocol.
. Plasmids
C-terminal green fluorescent protein (GFP)-tagged fusion protein versions of CD9 (RG202000; OriGene Technolo-
gies, Rockville, MD, USA) or VAP-A (HG11412-ACG; Sino Biological, Beijing, China) were expressed in vectors
pCMV6-AC-GFP or pCMV3-C-GFPSpark, which contain neomycin and hygromycin resistance genes, respectively.
For gene knockdown, shRNA plasmids targeting VAP-A (HSH022333-nH1; Accession No. NM_003574.5), VAP-B
(HSH022331-nH1; NM_004738.3), and ORP3 (HSH006982-nH1; NM_015550.2) were purchased from GeneCopoeia
(Rockville, MD, USA). A scrambled shRNA plasmid (CSHCTR001-nH1; GeneCopoeia) was used as control. These
plasmids contain the puromycin resistance gene. For each protein of interest, a pool of target sequences was uti-
lized after their individual evaluation, as described previously (Santos et al., 2018). Two distinct shRNA plasmids
were selected for VAP-A (5′- CCACACAGTGTTTCACTTAAT-3′ and 5′- GCACATTGAGTCCTTTATGAA-3′) and
VAP-B (5′- GGATGACACCGAAGTTAAGAA-3′ and 5′- GGTAAATTGGATTGGTGGATC-3′), whereas four shRNA
plasmids were selected for ORP3 (5′- CCATGTTTCCACATGAAGTTA-3′, 5′-CCTCCAATCCTAATTTGTCAA-3′, 5′-
GCCCATAAAGTTTACTTCACT-3′, and 5′- GGAGAAACATATGAATGTATT-3′).
. Transfection
FEMX-I cells were transfectedwith CD9-GFP plasmid (500 ng) using FuGeneHDTransfection Reagent (#E2311, Promega,Madi-
son,WI, USA) or VAP-A-GFP plasmid using Lipofectamine 3000 (#L3000008, Thermo Fisher Scientific). Transfected cells were
selected by introducing 400 μg/ml of Geneticin (G418 Sulphate, #10131027, Thermo Fisher Scientific) or 200 μg/ml of hygromycin
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(#H3274, Sigma-Aldrich) into the culturemedium. To inhibit VAP-A, VAP-B, or ORP3 expression, SW480 cells were transfected
with pooled shRNA plasmids (500 ng) using lipofectamine 3000. After transfection, stable cell lines were selected by 1 μg/ml
puromycin (#P9620, Sigma-Aldrich) for 7 days. All selection antibiotics were removed from the medium at least 1 week before
experiments.
. Baculovirus-based expression
The baculovirus-based BacMam 2.0 CellLight Late Endosomes-red fluorescent protein (RFP) fusion protein and ER-GFP or
-RFP (#C10589, #C10590 and #C10591, respectively, Thermo Fisher Scientific) were used to induce the expression of Rab7-RFP
and GFP or RFP fused to the ER signal sequence of calreticulin and KDEL, which highlight late endosomes and ER, respectively.
Viral particles were added at a concentration of 30 per cell for 24–48 h, as recommended by the manufacturer, prior to imaging
by live video microscopy or after fixation (see below).
. Isolation and characterization of EVs
EVs were prepared from parental SW620 or CD9-GFP-transfected FEMX-I cells (250,000 cells) cultured in 5 ml serum-free
medium supplemented with 2% B-27 supplement (#17504044, Thermo Fisher Scientific) on 6-well plates pre-coated with
20 μg/ml poly(2-hydroxyethyl methacrylate) (#P3932, Sigma-Aldrich) to prevent their attachment as described (Rappa et al.,
2017). After 72 h, EVs were enriched by differential centrifugation. Briefly, after low-speed centrifugations (300 and 1200 ×
g) of conditioned medium, the supernatant fluid was centrifuged at 10,000 × g for 30 min at 4◦C. The pellet was discarded
and the resulting supernatant fluid centrifuged at 200,000 × g for 60 min at 4◦C (Figure 1a). The pellet was resuspended in
200 μl PBS. The size and concentrations of EVs derived from parental SW620 cells or CD9-GFP-transfected FEMX-I cells were
150 and 120 nm, and 4 × 1010 and 2 × 1010 particles/ml, respectively, as determined by nanoparticle tracking analysis using
ZetaView (software version: 8.05.10; Particle Metrix GmbH, Meerbusch, Germany) according to the manufacturer’s protocol.
The following parameters were used: 488 nm laser in scatter mode, video duration of 2 s at 30 frames per second for 11 positions
along the z-axis of the analysis window, camera gain of 10, and trace length of 15. EVs were characterized for the presence (CD9,
CD81, CD63, and Alix) or absence (histone H1, calnexin) of particular proteins by immunoblotting (see below) according to
the guidelines of the International Society for EVs (MISEV2018) (Théry et al., 2018). We have submitted all relevant data of our
experiments to the EV-TRACK knowledgebase (EV-TRACK, https://evtrack.org/, ID: EV210180) (EV-TRACK Consortium
et al., 2017).
. Cell–EV incubation
Parental SW480 cells or those treated to knockdownORP3, VAP-A, and VAP-B as well as FEMX-I and HeLa cells were seeded at
a density of 1× 105 cells/ml on poly-D-lysine-coated glass-bottom dishes in a final volume of 1 ml of complete cell medium. Upon
attachment, 1 × 109 particles (26 μg proteins) or 2 × 109 particles derived from either SW620 or CD9-GFP-transfected FEMX-I
cells in 5 or 10 μl PBS, respectively, were added for 5 h at 37◦C. Afterward, cells were processed for immunocytochemistry and
subsequent analysis by confocal microscopy. See below for the scratch wound healing assay.
. Drug treatments
SW480 cells (1 × 105) were incubated for 5 h with various concentrations of ICZ (2, 5 and 10 μM), H-ICZ (2, 5 and 10 μM),
ketoconazole (10 μM), thapsigargin (1 μM), imipramine (100 μM), OSW-1 (50 nM), PRR851 (10 μM) or PRR846 (10 μM) as
indicated at 37◦C. As a control, cells were incubated with DMSO alone. For the thapsigargin rescue experiment, cells were
first treated with thapsigargin for 1 h prior to the addition of ICZ (10 μM). They were then incubated for an additional 5 h
and processed for immunoisolation and immunofluorescence as described below. In some experiments, EVs were added to
recipient cells after a 10-min pre-incubation with drugs and further incubated for 5 h in the continuous presence of the drugs.
Alternatively, ICZ, H-ICZ, ketoconazole, PRR851 and PRR846 at the indicated concentrations (1–10 μM) were directly added to
detergent cell lysates prepared from SW480 cells (see below) for 30 min on ice with occasional mixing prior to immunoisolation
as described below. In the competitive assay, detergent cell lysates were pre-incubated with 25-HC at various concentrations
(1, 3, 10, 30 or 100 μM) for 30 min on ice, and then ICZ or PRR851 (10 μM) was added for 30 min. For the dephosphorylation
experiments, λ-phosphatase (2000 U/ml) was added to detergent cell lysates and the reaction was supplemented with 2 mM
MnCl2. The lysates were incubated for 3 h at 30◦C. As a control, no enzyme was added. ORP3 was then immunoisolated
(see below).
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F IGURE  Characterization of EVs derived from SW620 and CD9-GFP+ FEMX-I cells. (a) Schematic representation of the differential centrifugation
protocol used to enrich EVs from the conditioned media of SW620 or CD9-GFP+ FEMX-I cells. (b) The 200,000 × g pellets containing EVs were analysed by
immunoblotting for CD9, CD81, CD63, Alix, histone H1 (H1) and calnexin (CNX). Arrow and arrowhead indicate the CD9-GFP fusion protein and the
endogenous CD9, respectively. Molecular mass markers (kDa) are indicated. (c) The size and concentration of EVs were characterized using the ZetaView
particle analyser. (d–f) EVs were imaged using dSTORM (d, f) or TEM (e). Upon immunolabelling, the proteins of interest (CD9, CD63 and CD81) were
pseudo-coloured as indicated. Single-, double- and triple-positive EVs were shown and quantified (d, f) (n ≥ 4000 EVs; three independent measurements). The
percentage of each is shown and/or presented in the pie chart (d, f). Representative TEMmicrograph revealed diverse shape and size of EVs (e, insets). Scale
bars, 1 μm (d, f, overview, e), 100 nm (d, f, inset)
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. Immunoisolation and immunoblotting
Parental SW480 cells or those deficient in VAP-A orORP3were solubilized in pre-chilled lysis buffer (0.5%Triton X-100, 150mM
NaCl, 50 mM Tris-HCl, pH 8.0, supplemented with Set III protease inhibitor cocktail (#539134, Calbiochem, Merck)) on ice for
30min, followed by centrifugation (12,000× g) for 10min at 4◦C. In some experiments, 500mM instead of 150mMofNaCl or 1%
instead of 0.5% Triton X-100 were used. Immunoisolations were performed on detergent cell lysates using an Ab directed against
human ORP3 or VAP-A followed by Protein G-conjugated magnetic beads according to the manufacturer’s protocols (#130-
071-101, Miltenyi Biotec, Bergisch Gladback, Germany). Samples were applied to μ Columns (#130-042-701, Miltenyi Biotec) for
magnetic separation. Materials retained in columns were washed (4x) with 1 ml lysis buffer and rinsed once with 20 mM Tris-
HCl pH 7.5. Pre-heated (95◦C) sodium dodecyl sulphate (SDS) buffer (1% SDS, 50 mMDTT, 1 mM EDTA, 10% glycerol, 0.005%
bromophenol blue, 50 mM Tris-HCl, pH 6.8) was applied to the column to elute the bound fractions. For EV immunoblotting,
the SDS buffer was added to the enriched EVs and heated at 95◦C for 5 min.
Protein samples were separated onto a 4–20% Tris-glycine precast gel (#4561095, Bio-Rad, Hercules, CA, USA) along with the
Trident pre-stained proteinmolecular weight ladder (#GTX50875, GeneTex, Irvine, CA,USA), and transferred to a nitrocellulose
membrane (#88018, Thermo Fisher Scientific) overnight at 4◦C.Membranes were incubated in a blocking buffer (PBS containing
1% BSA) for 60 min at room temperature (RT), and then probed with a given primary Ab (Table S1) for 90 min at RT. After three
washing steps of 10 min each with PBS containing 0.1% Tween 20 (washing buffer; VWR International), the membranes were
incubated with appropriate fluorescein isothiocyanate (FITC)-coupled secondary Abs diluted in blocking buffer for 30 min at
RT. The membranes were rinsed three times with washing buffer, once with distilled and deionized H2O and the antigen-Ab
complexes were visualized using the iBright FL1000 imaging system (Thermo Fisher Scientific).
. Mass spectrometry
The proteins eluted in Laemmli buffer from ORP3- or VAP-A-mediated immunoisolation were passed through home-made
suspension trapping filters for clean-up as previously described (Zougman et al., 2014). The suspension trapping filters were
fashioned from 8 × 3 mm punches of QM-AWhatman quartz discs, stacked above two layers of C18 resin (Empore C18, 3 M) in
a 200μl pipet tip (Zougman et al., 2014). Thiswas filledwith 100mMTris-HCl (pH7.4) inmethanol. The sampleswere solubilized
with SDS (4%wt/vol.) containing 20mMDTT and incubated at 95◦C for 5 min, then alkylated with chloroacetamide in the dark
for 30 min. Phosphoric acid was added to 3% and the sample transferred to the trapping pipet. Proteins were captured on quartz
fibres as a fine dispersion while MS-incompatible materials passed through the tip. The stack was rinsed and refilled with cold
trypsin solution in 50 mM AmBiC and set to digest at 47◦C for 2 h. Peptides were eluted with 300 μl of 50% acetonitrile and
0.1% trifluoroacetic acid, lyophilized and stored at -20◦C. Immunoprecipitated samples were labelled with TMT10plex isobaric
labels (Thermo Fisher Scientific), which adds 229.163 Da tags onto lysine residues and the peptide N-terminus. This afforded
precise comparison of recoveries across targeted ORP3 and VAP-A pull downs. For more details see Supplementary Materials
and Methods in Supporting Information section.
For LC/MS/MS, approximately 200 ng of 10-plex sample mixture was resolved on a 200 cm μPac column (PharmaFulidics,
Ghent, Belgium) with a 155-min gradient propelled by a Proxeon NanoLC 1200 UHPLC. Full data were acquired on a Fusion
Orbitrap LUMOS (Thermo Fisher Scientific) running an SPS MS3 protocol as described (Yu et al., 2015). This consists of an
orbitrapMS1 scan acquired every 2 s at 60,000 full width at halfmaximum (FWHM) resolutionwhile fullMS2 data is acquired on
the Linear Ion trap with a mass isolation window of 0.7 Da. The linear trap is then set to synchronously isolate 10 MS2 fragments
retaining the TMT tag to perform high energy activation in the ion routing multipole and injection in the orbitrap where the
reporter ions (126-131 Da) are measured with 50,000 FWHM resolution at 200 Da. A 30-s dynamic exclusion improved selection
of lower abundant precursors. Proteome searches were performed with Proteome Discoverer 2.4 (Thermo Fisher Scientific)
and MaxQuant (Cox & Mann, 2008) against the 7/12/2019 human UniprotKB and reverted entry database. With 5 and 10 ppm
tolerance for precursor and fragments, respectively, searches assume fixed Cys modifications of 57 Da as well as variable mods
of 16 (M) and 80 (S, T) Th. Final discriminant scores were determined by the individual search programs maintaining a false
discovery rate (FDR) inferior to 0.02.
. Immunocytochemistry
Cells grown on 35-mm poly-D-lysine-coated glass-bottom dishes (MatTek Corporation, Ashland, MA, USA) were processed
for immunocytochemistry after drug treatment, and/or upon incubation with EVs. Cells were washed with PBS, fixed in 4%
paraformaldehyde (PFA) in PBS for 15 min, washed twice with PBS, permeabilized with 0.2% Tween 20 in PBS for 15 min, and
blocked with 1% bovine serum albumin (BSA, #97061-420, VWR International) for 1 h at RT. They were then incubated with
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primary Abs (Table S1) against specific proteins as indicated in each figure for 60 min at RT, washed twice with PBS, incu-
bated with appropriate fluorescent secondary Abs (Table S2) for 30 min, and washed twice prior to observation. All Abs were
diluted in permeabilization buffer containing 1% BSA. To analyse cell morphology, the anti-CD9 Ab was added to PFA-fixed,
non-permeabilized cells. Alternatively, cells were stained with ActinGreenTM488 ReadyProbes (#R37110, Thermo Fisher Scien-
tific) for 30 min at RT. Nuclei were counterstained with DAPI. In some experiments, after immunolabelling, cells were incubated
with filipin at 50 μg/ml working concentrations for 2 h at 20◦C and then washed twice with PBS. Cells were imaged in PBS
using either the Nanoimager high-resolution microscope (ONI, Oxford, UK) with 100X oil-immersion objective or the Nikon
A1R+ inverted confocal microscope (Nikon, Melville, NY, USA) with a 60X Apo-TIRF oil-immersion objective. All images were
acquired under the samemicroscope settings for subsequent calculations ofmean fluorescence and recorded usingNanoimaging
(ONI) or NIS Elements software (Nikon). Fluorescence signal was quantified using Fiji software (Schindelin et al., 2012). Tomea-
sure the cytoplasmic-associated GFP signal upon incubation of cells with CD9-GFP+ EVs, regions of interest (ROIs) were drawn
around the cytoplasm of SUN2-immunolabelled cells, excluding the nuclear compartment, and the ‘measure’ function on Fiji was
applied to determine the fluorescent signal. The total cell fluorescence was then calculated as total cell fluorescence= integrated
density – (area× backgroundmean fluorescence). To determine the nuclear EV-derived fluorescent materials, ROIs were plotted
along the nucleus and an automatic threshold generated by Fiji was applied as described (Rappa et al., 2017). Positive signals were
counted using the ‘analyse particle’ function and presented as dot plots.
. Stochastic optical reconstruction microscopy
Three-dimensional (3D) direct stochastic optical reconstruction microscopy (dSTORM) was applied either on cells or EVs. In
the case of cells, SW480 cells were seeded at a density of 5 × 104 cells/ml on 8-well glass-bottom (#1.5H thickness) μ-slides
(#80827, Ibidi, Fitchburg, WA, USA). They were treated without or with 10 μM drugs (ICZ, PRR851) for 5 h, PFA-fixed and
permeabilized with 0.2% Tween 20 in PBS for 15 min each. They were blocked with 1% BSA, 0.2% Tween 20 in PBS for 1 h and
then double labelled with primary Abs against ORP3 or Rab7 for 1 h at RT. Appropriate secondary Abs conjugated to Atto 488
(#610-152-121, Rockland Immunochemicals, Limerick, PA, USA) or Alexa Fluor647 (#A-21246, Thermo Fisher Scientific) were
applied for 30 min. Cells were post-fixed in 4% PFA. Cells were imaged using a Nanoimager high-resolution microscope with
100X oil-immersion objective. A STORM-imaging buffer was used to attain the ‘blinking’ event of the dyes required in imaging
process. It is a random activation of the dyes from an off or dark state to an on or emission state and back, thus allowing single
particle illumination (Rust et al., 2006). The buffer consists of glucose oxidase (0.5 mg/ml, #G2133, Sigma-Aldrich), catalase
(40 μg/ml, #C1345, Sigma-Aldrich), glucose (10% m/v), and 2-mercaptoethylamine (10 mM, #30070, Sigma-Aldrich) diluted
in Tris-buffered saline (50 mM Tris-HCl, pH 8.0, 10 mM NaCl). Prior to imaging, channel and 3D mapping calibrations were
performed using 0.1 μmTetraSpeck beads (#T7279, Thermo Fisher Scientific). Lasers (488 and 640 nm) were set to 100% power
and 10,000 frameswere acquired per channel sequentially, collecting about 100–250 particles per frame. The thickness of acquired
sections is 1 μm. Drift correction was applied to each image using the built-in function of ONI’s NimOS software. ROIs were
drawn on the entire areas of cytoplasm, perinuclear zone and NEI then rendered in 3D image using Imaris software by Bitplane
(Concord, MA, USA). A modelling of the protein of interests was generated using the ‘spots’ and ‘surface’ functions. Then, the
distance between two structures (i.e., ORP3 or Rab7 positive) were calculated using the ‘statistics’ function. ROIs were made also
around the plasma and nuclear membranes to evaluate the volume of Rab7+ structures in the pericellular and perinuclear zones,
respectively. A filter was applied to show structures with a volume greater than 20 nm3.
EVs prepared from SW620 or CD9-GFP+ FEMX-I cells (3.5 × 107 and 1.1 × 108 particles, respectively) were immunola-
belled overnight at 4◦C using a cocktail of fluorescently labelled anti-tetraspanin Ab against CD9 (Atto488 mouse anti-human
monoclonal; FL-REA-EV-CD9-Atto488), CD63 (Cy3BTM mouse anti-humanmonoclonal; FL-REA-EV-CD63-Cy3b), andCD81
(Alexa Fluor®647 rat anti-humanmonoclonal; FL-REA-EVCD81-AF647). CD9-Alexa Fluor®647 was used for CD9-GFP+ EVs.
In the latter case, we did not use the green channel to avoid crosstalk between the immunostaining and the GFP signal. Stained
EVs were loaded and captured on the surface of a PEG-Biotin functionalized microfluidic chip included in the EasyVisi Single-
Extracellular Vesicle Characterization kit from ONI (beta version 1.0, Oxford Nanoimaging, UK). Surface preparation, removal
of unbound Ab, and crosslinking of EVs to the chip surface, including all wash steps, were performed using the EasyVisi kit
and automated using a Roboflow microfluidic sample preparation platform (ONI). Freshly prepared BCubed STORM-imaging
buffer (ONI) was added to each lane on the microfluidics chip before imaging. Single-molecule fluorescence data consisting of
2000 frames per channel, was sequentially acquired using the Nanoimager S Mark II with laser power set to 45, 50, and 50% for
the 640, 560, and 488 lasers, respectively. An Olympus 1.4NA 100x oil immersion super apochromatic objective was used with
angle of illumination set to 52.5◦. Channel mapping was calibrated at the start of the imaging session using 0.1 μm Tetraspeck
beads (Thermo Fisher Scientific). Data was processed onNimOS software (version 1.18; ONI). To identify EV subpopulations that
express one, two, or three markers, single-molecule data was analysed using algorithms developed by ONI via their online local-
ization microscopy data analysis platform beta-released named CODI (https://alto.codi.bio/, releases 0.16.0 to 0.14.1; 9 March
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2021 to 28 April 2021). The analysis workflow of EV data included filtering, drift correction, and subsequent clustering using
hierarchical density-based clustering algorithms for single-EV analysis.
. Incubation of fluorescent drug
ER-RFP-expressing SW480 cells were incubated with the green-fluorescent compound PRR898 (2 μM) for 1 h, then washed
with RPMI medium and further incubated for the indicated time. They were then fixed with 4% PFA and imaged using the
Nanoimager microscope.
. Time-lapse video microscopy
SW480 cells expressing ER-GFP and Rab7-RFP or FEMX-I cells expressing VAP-A-GFP and Rab7-RFP grown on 35-mm poly-
D-lysine-coated glass-bottom dishes (Mattek) were treated with ICZ or H-ICZ (see above) and then imaged live under 5% CO2
atmosphere at 37◦C. For SW480 cells, time-lapse videos were recorded every 20 s for a period of 5 min using the Nanoimager
microscope, whereas the images of FEMX-I cells were acquired every 60 s for a 10 min-period using the A1R+ confocal micro-
scope. Videos were made at a playing speed of one or three frames per second as indicated, and a single x-y optical section
(0.2 μm) was acquired at a given time. The tracking and the velocity of Rab7+ structures were evaluated using TrackMate plugin
available in the Fiji software (Tinevez et al., 2017).
. Electron microscopy
The EVs recovered from 200,000 × g pellet were prepared for transmission electron microscopy (TEM) using negative staining.
A 5-μl aliquot of EV suspension was applied onto 200-mesh carbon-coated EM grids. After subsequent washing steps with PBS,
the grids were fixed for 5 min in 1% glutaraldehyde in PBS. The sample was negatively contrasted with 2% aqueous solution of
phosphotungstic acid. The grids were viewed in a JEOL JEM 1400 Plus electronmicroscope operated at 80 kV. The images shown
were prepared using Adobe Photoshop software.
. Cell migration assay
Cell migration was evaluated by a scratch wound healing assay. SW480 cells were seeded at concentration of 2 × 105 cells/well in
12-well plates. Once the cells reached full confluence, the wound healing assay was performed by scratching the cell monolayer
with a sterile pipette tip. The cells were washed to remove detached cells, and then treated without or with 10 μM drugs (ICZ or
PRR851) for 5 h in the absence or presence of SW620 cell-derived EVs (7.5 × 108 particles/ml or 20 μg protein/ml). Images of
scratch wounds were captured using an invertedmicroscope (Olympus IX70, Segrate, Italy) before (0 h) and after (5 h) treatment.
The wound areas were measured with ImageJ (Schindelin et al., 2012). At least 10 fields/conditions were analysed from two
independent experiments. For each condition, the Wound Area at 0 h was considered as the 100%.
. Growth inhibition assay
Cells were seeded at a density of 4 × 103 cells on 96-well plates and incubated overnight to allow their adhesion. They were
then treated with ICZ, H-ICZ, ketoconazole, PRR851 and PRR846 at different concentrations (1, 3, and 10 μM) for a given time
(24, 48 and 72 h), as indicated. DMSO was used as control. At the appropriate time, a CellTiter96 AQueous One Solution Cell
Proliferation Assay (1:5 dilution; #G3580, Promega) was added for 2 h at 37◦C. The reagent utilizes the biochemical reaction of
a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS]
to produce a coloured, soluble formazan product, that is, proportional to the number of live cells. The absorbance value was
measured at 490 nm using the Varioskan Flash plate reader (Thermo Fisher Scientific).
. Statistical analysis
All experiments were carried out at least in triplicate, with the exception of the cell migration assay, which was performed in
duplicate. The error bars in the graphical data represent the mean ± standard deviation (S.D.) or standard error of the mean
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(S.E.M.) as indicated in the figure legends. Statistical significance was determined using a two-tailed Student’s t-test, and P val-
ues < 0.05 were considered significant. All graphs were created using GraphPad Prism 8.
 RESULTS
. Itraconazole inhibits the EV-induced pro-metastatic morphological transformation
Numerous studies have demonstrated the pro-malignant impact of EVs derived from cancer cells on the surrounding environ-
ment, including cell transformation (Zomer et al., 2015; Zomer & van Rheenen, 2016). Non-metastatic elongated SW480 colon
cancer cells are an excellent model for determining EV-induced transformation. Compared to SW480 cells, highly metastatic
SW620 cells have a more rounded shape, associated with amoeboid motility and high plasma membrane blebbing activity (de
Toledo et al., 2012; Schillaci et al., 2017). These pro-metastatic properties can be transferred to SW480 cells by EVs derived from
SW620 cells (Schillaci et al., 2017). To assess whether these cellular alterations are related to the nuclear transfer of the EV cargo,
we exposed SW480 cells as well as those silenced for VAP-A, VAP-A homolog, VAP-B, and ORP3 for 5 h to EVs prepared from
SW620 cells. The lack of VOR complex proteins should impair the nuclear transfer of EV cargo, and potentially the malignant
transformation (Rappa et al., 2017; Santos et al., 2018).
The silencing of VAP-A, VAP-B and ORP3 in SW480 cells was achieved using the short hairpin RNA (shRNA) technol-
ogy (Santos et al., 2018). As a control, SW480 cells were stably transfected with a scrambled shRNA plasmid. Their reduction
was confirmed and quantified by immunofluorescence followed by confocal laser scanning microscopy (CLSM) analysis and
immunoblotting (Figure S1a-c). EVs released by SW620 cells were enriched by differential centrifugation of conditioned media
and characterized by immunoblotting, nanoparticle tracking, dSTORM and TEM analyses. They were positive for membrane
proteins CD9, CD81 and CD63 as well as for cytoplasmic protein Alix, which are characteristic constituents of EVs, while nuclear
histone H1 and ER-resident protein calnexin were absent (Figure 1b), in line with other studies (Jeppesen et al., 2019; Théry et al.,
2001; Théry et al., 2018). EVs ranged in size from 50 to 350 nm, suggesting the presence of exosomes and microvesicles (Fig-
ure 1c). Consistent with these observations, we visualized by dSTORM, a single molecule super-resolution technique, various
EV subpopulations as immunolabelled with tetraspanin proteins (Figure 1d). The triple positive (CD9, CD63, and CD81) EVs
represent the major subpopulation in agreement with others (Kowal et al., 2016). The CD9–CD63+CD81+ EVs constitute the
second abundant subpopulation, while EVs labelled only with one of them represent a minor fraction. The heterogeneity in EV
size is also confirmed by TEM where the diameter of EVs varies from small (< 60 nm), intermediate (60–90 nm), and large
(> 90 nm) (Figure 1e), in agreement with other studies (Chen et al., 2019; Endzeliņš et al., 2018; Popēna et al., 2018).
Upon exposure to SW620 cell-derived EVs, SW480 cells were immunolabelled for CD9 (or labelled with ActinGreenTM488
ReadyProbes) and observed by CLSM. Their shape and membrane blebbing changed significantly as scored by two independent
investigators (Figure 2a, b), in agreement with a previous report from one of our labs (Schillaci et al., 2017). This phenotype was
abolished upon ORP3 or VAP-A knockdown. These events are specific for VOR complex proteins since VAP-B silencing did
not block them (Figure 2a, b). These data suggest that the nuclear transfer of the EV cargo is involved in the aforementioned
phenotype.
We assessed whether ICZ could interfere with EV-mediated pro-metastatic morphological transformation. We pre-treated
SW480 cells with 5 or 10 μM ICZ or its major metabolite H-ICZ for 10 min prior to incubation with SW620 cell-derived EVs
for 5 h. The drugs were kept during EV incubation. As a negative control, cells were incubated with the solvent vehicle only (i.e.,
0.1% DMSO). Similar to the ORP3 or VAP-A knockdown, ICZ prevented the rounding and/or blebbing of cells (Figure 2c-e).
H-ICZ did not avert these EV-mediated changes. Indeed, H-ICZ partially reduced the number of rounded and blebbed SW480
cells under native conditions, that is, without the addition of EVs (Figure S2). These data suggest that ICZ inhibited the nuclear
transfer of the EV cargo, thus interfering with the malignant transformation.
To visualize the nuclear transfer of the EV cargo, and the impact of ICZ on it, we used an assay previously developed in our
laboratory, where bioengineered fluorescent EVs are incubated with host cells prior to quantification of internalized cytoplasmic
and nuclear fluorescent signals (Rappa et al., 2017; Santos et al., 2018). The EVs were enriched from conditioned media of CD9-
GFP+ FEMX-I cells and characterized such as those described above (Figure 1b, c, d, f). The human melanoma cell line FEMX-I
has been used to identify the VOR complex (Santos et al., 2018), and the morphology of EVs derived from it has already been
documented by CD63-immunoelectronmicroscopy (Rappa et al., 2013b). Three cell lines, SW480, FEMX-I and HeLa cells, were
pre-treated without or with 2 or 10 μM ICZ for 10 min prior to incubation with CD9-GFP+ EVs for 5 h. Subsequently, fixed-cells
were immunolabelled for SUN domain-containing protein 2 (SUN2) to highlight the nuclear compartment. They were analysed
by CLSM through serial x-y optical sections (25–30 sections per cell, 0.2 μm each) covering the entire cell of interest. Fluorescent
cytoplasmic and nuclear signals (i.e., GFP) were quantified. For all cell lines, no reduction in the overall intensity of cytoplasmic
GFP in the host cells were found suggesting that ICZ does not block EV endocytosis (Figure S3a-c), which is consistent with
a recent report (Lin et al., 2018). In contrast, discrete nuclear GFP punctate signals distributed throughout the nucleoplasm
decreased significantly upon incubation with 2 or 10 μM ICZ (Figure 2f-h; Table S4; see also Figure S3d), indicating that ICZ
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F IGURE  Silencing VOR complex or the ICZ
treatment inhibits EV-induced pro-metastatic
morphological transformation and nuclear transfer
of EV cargo in SW480 cells. (a, b) Non- metastatic
SW480 cancer cells (scrambled shRNA control) and
those treated to knock down ORP3 (shORP3),
VAP-A (shVAP-A) and VAP-B (shVAP-B) were
incubated for 5 h without or with EVs (1 × 109
particles/ml) derived from metastatic SW620 cells
prior to CD9 immunolabelling. Nuclei were
visualized with DAPI and cell morphology was
analysed by CLSM (a). Bar graphs show the
percentage of cells harbouring a rounded
morphology (left) or membrane blebbing (right)
upon exposure to EVs (b). (c-e) SW480 cells were
pre-treated with DMSO (control) or 5 and 10 μM
ICZ (c-e) or H-ICZ (d, e) for 10 min prior to the
addition of SW620 cell-derived EVs and then
incubated for 5 h. Cells were stained for actin
(ActinGreen, green) and nuclei (DAPI, blue) (c). Bar
graphs show the percentage of cells harbouring a
rounded morphology (d) or membrane blebbing (e).
At least 100 cells were evaluated per condition and
independent experiment (b, n= 11–12; d, e, n= 5–6).
Arrowheads and asterisks indicate the rounded cell
morphology and the membrane blebbing induced
by EVs. (f-h) SW480 (f), FEMX-I (g) and HeLa (h)
cells were pre-treated with DMSO (control) or 2 and
10 μM ICZ for 10 min prior to 5-h incubation with
FEMX-I cell-derived CD9-GFP+ EVs (1 × 109
particles/ml) in the absence or presence of drugs.
Cells were fixed and immunolabelled for SUN2. The
CD9-GFP signal in the nuclear compartment was
analysed by CLSM and quantified. Independent
values for each cell (n = 50 per condition) from a
representative experiment are displayed (f-h). In all
cases, means ± S.D. are shown. P values are
indicated. The quantification of three independent
experiments for each cell line is presented in Table
S4. N.s., not significant. Scale bars, 5 (a) or 20 (c) μm
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interferes with the nuclear transfer of EV cargo. Overall, this first set of experiments demonstrated that ICZ phenocopies the
silencing of ORP3 and VAP-A by inhibiting EV-mediated cell transformation. It remains to be determined whether the observed
effects are related to the impact of ICZ on the integrity of the VOR complex, and possibly the absence of late endosomes in the
nucleoplasmic reticulum.
. Identification of ICZ as a VOR complex inhibitor
To evaluate whether ICZ interfered with the interaction of ORP3 with VAP-A and/or Rab7, we set up a co-immunoisolation
protocol based on paramagnetic bead separation (Santos et al., 2018). Two distinct Abs against humanORP3, the antiserum (AS)
A304-557A and monoclonal Ab D-12, were used (Figure S4a). By immunoblotting SW480 cell lysate prepared with a lysis buffer
containing 0.5%Triton X-100 and 150mMNaCl, both Abs recognized a broadORP3 immunoreactive band (∼95 to 100 kDa; Fig-
ure S4b). The ORP3 immunoreactivity often appeared as a very close doublet, which could correspond to the hyper- (∼101 kDa)
and hypo-phosphorylated (∼97 kDa) forms of the protein (Weber-Boyvat et al., 2015). Coupled with magnetic beads conjugated
to G protein, Ab D-12 could selectively pull down ORP3 together with VAP-A and Rab7 as observed by immunoblotting (Figure
S4c) and liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis of D-12 immunoisolated materials, where
peptides of three proteins were recovered (Figure S4d; Table S5).
Upon 5-h incubation of SW480 cells with ICZ or H-ICZ (10 μM), cells were solubilized prior to immunoisolation using anti-
ORP3 D-12 Ab. As a negative control, cells were incubated with the solvent vehicle only. The immunoisolated materials were
probed by immunoblotting forORP3, VAP-A andRab7. ICZ, but notH-ICZ, completely abolished the interaction ofORP3/VAP-
A with Rab7, while the ratio of ORP3 and VAP-A was unaffected (Figure 3a-c), suggesting that the potential binding of ICZ to
ORP3 interferes with ORP3–Rab7 interaction. Since the observed effect of ICZ could be caused by various intracellular factors,
we added the drugs to detergent cell lysates in the cold, instead of living cells, prior to ORP3 immunoisolation. The interaction
of ORP3/VAP-A with Rab7 in the lysates was also disrupted by ICZ (Figure 3d-f), suggesting that this compound acts directly
on the VOR complex. The inhibition of ORP3/VAP-A–Rab7 interaction was also observed at lower concentrations (i.e., 2 and
5 μM ICZ), although less effectively (Figure 3g, h).
The immunoisolation data obtained from ICZ-treated cell lysates suggest a direct interaction between the three VOR complex
proteins. In agreement with this conclusion, when cells were solubilized in the presence of a high-ionic strength buffer containing
500 instead of 150 mM NaCl, which disrupts most ionic protein interactions, VAP-A and Rab7 were not co-immunoisolated
with ORP3 (Figure 4a-c). Increasing the concentration of the Triton X-100 detergent from 0.5 to 1.0% in the solubilization buffer
prevented the co-immunoisolation of Rab7withORP3, but did not disrupt the binding of VAP-A toORP3, reflecting the stronger
binding of ORP3 with the integral membrane protein VAP-A than with the lipid-anchored Rab7. These data suggest that ICZ
perturbed the interaction ofORP3/VAP-AwithRab7,which eventually impedes the entry of late endosomes intoNEI (see below).
To further dissect the ORP3/VAP-A–Rab7 interaction, we used VAP-A-deficient SW480 cells. These cells, as well as control
cells transfected with a scrambled shRNA plasmid, were solubilized and then subjected to ORP3 immunoisolation. Immunoblot-
ting of ORP3, VAP-A and Rab7 showed that VAP-A is required for the interaction of ORP3 with Rab7 (Figure 4d, e). In contrast,
when a similar experiment was carried out with cells deficient in VAP-B (Figure S1a-c; Figure S4e), the ORP3–Rab7 interaction
remained intact (Figure 4e). This information suggests that VAP-A could be involved either in a conformational change of ORP3
that allows its subsequent interaction with Rab7, or that both VAP-A and ORP3 are required for Rab7 binding. It is documented
that the interaction of ORP3 with VAP-A is strongly stimulated by the hyperphosphorylation of ORP3 (Weber-Boyvat et al.,
2015). In agreement with the latter, λ-phosphatase treatment of detergent SW480 cell lysates prior to ORP3 immunoisolation
completely suppressed the interaction with VAP-A as well as with Rab7 (Figure 4f), suggesting that phosphorylated ORP3–VAP-
A interaction is a prerequisite for Rab7 binding. The efficacy of phosphatase treatment was validated by a perceptive change in
the mobility of ORP3.
The role of ORP3 in the VOR complex was then investigated using ORP3-deficient cells (Figure S1a-c; Figure S4f, g). The
immunoisolationwas performedwith anti-VAP-AAb (Figure 4g). As described for ORP3-driven immunoisolation, we observed
under native conditions a co-isolation of the three VOR complex proteins by immunoblotting (Figure 4h; Figure S4f) or
LC/MS/MS analysis (Figure S4d; Table S5). The large difference in ORP3/VAP-A ratios observed upon VAP-A- versus ORP3-
driven immunoisolation (Figure 4h, i) is indicative of other types of VAP-A interactions beside the VOR complex (Figure 4g).
In line with the indirect interaction of VAP-A-Rab7 via other OSBP-related proteins, ORP3 knockdown did not impede the co-
isolation of VAP-A and Rab7 (Figure S4f, g). Of note, cell exposure to ICZ did not affect the binding of Rab7, as observed by
VAP-A-driven immunoisolation opposed to the ORP3-driven immunoisolation (Figure 4h-j; Figure S4f, g), suggesting that ICZ
blocks the interaction of ORP3 and Rab7, but not that of other OSBP proteins and Rab7 (Figure 4g).
In summary, this second set of experiments suggests that there are at least two distinct sets of VAP-A-Rab7 interactions –
the established one, ICZ-insensitive, possibly observed at the ER membrane where it could participate in the maturation and
positioning of late endosomes (Eden, 2016) and involve the cholesterol sensor ORP1L (Rocha et al., 2009), and the ICZ-sensitive
one involving ORP3, which regulates the entry of late endosomes into nucleoplasmic reticulum (Figure 4g) (Santos et al., 2018).
It remains to be established whether the latter occurs at the gate of, and/or within, type II NEI.
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F IGURE  ICZ disrupts the binding of Rab7 to ORP3 and VAP-A. (a-c) SW480 cells were incubated with either DMSO (control), 10 μM ICZ or H-ICZ
for 5 h, solubilized and subjected to immunoisolation (IS) using anti-ORP3 Ab followed by Protein G-coupled magnetic beads. The input (1/50) and entire
bound fractions were probed by immunoblotting for ORP3, VAP-A and Rab7 (a). The ratio of protein immunoreactivities of the indicated pairs was quantified
(b, c, n = 3). (d–f) The SW480 cell detergent lysate was divided in three aliquots and incubated with DMSO (control), 10 μM ICZ or H-ICZ for 30 min on ice,
and then subjected to IS with anti-ORP3 Ab and immunoblotting (d). The input (1/50) and bound fractions were analysed. The ratio of protein
immunoreactivities of the indicated pairs was quantified (e, f, n = 3). (g, h) SW480 cells were exposed to different ICZ concentrations as indicated for 5 h,
solubilized and subjected to IS and immunoblotting (g). As controls, no solvent (–) or DMSO (0.1%) were used. The ratio of protein immunoreactivities of the
indicated pairs was quantified (h, n = 3). For all immunoblots, molecular mass markers (kDa) are indicated, and arrows point to the proteins of interest. The
mean ± S.D. are shown. P values are indicated. N.s., not significant
. Itraconazole impedes the localization of Rab+ late endosomes in the nucleoplasmic
reticulum
To determine the impact of ICZ on the subcellular localization of Rab7+ late endosomes, particularly with respect to their entry
into the nucleoplasmic reticulum, SW480 cells were treated with either 10 μM ICZ or H-ICZ, or DMSO as a negative control, for
5 h and double immunolabelled for VAP-A andORP3 or Rab7. Cells were observed by CLSM. Although the occurrence of ORP3
in VAP-A+ NEI was unaffected by drugs (Figure 5a), Rab7 was absent in the presence of ICZ, but not of H-ICZ (Figure 5b). The
reduction in total Rab7+ VAP-A+ NEI was approximately 65% (Figure 5c). To obtain information on the transport of Rab7+ late
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F IGURE  ICZ disrupts the binding of ORP3 to Rab7, but not to VAP-A. (a-c) SW480 cells were solubilized in the presence of different concentrations of
NaCl or Triton X-100 as indicated prior to being subjected to immunoisolation (IS) using anti-ORP3 Ab and Protein G-coupled magnetic beads. The bound
fraction was probed by immunoblotting for ORP3, VAP-A and Rab7 (a). The ratio of protein immunoreactivities of the indicated pairs was quantified (b, c,
n = 3). (d, e) Detergent lysates prepared from parental (scrambled control) and VAP-A-silenced (shVAP-A) SW480 cells were processed as described in panel
a. The input (1/50) and bound fractions were analysed by immunoblots (d). The ratio of protein immunoreactivities of the indicated pairs was quantified (e,
n = 3; see Figure S4e for corresponding blot of SW480 shVAP-B data). (f) The detergent lysate prepared from SW480 cells was divided into two aliquots and
incubated without (control) or with λ-phosphatase (Phos.) for 3 h prior to ORP3 immunoisolation and immunoblotting. It should be noted that there were no
slower-migrating ORP3 immunoreactive species after phosphatase treatment. (g) Diagram illustrating the tripartite protein complex interactions between
VAP-A (yellow), Rab7 (red) and ORP3 (green) or another oxysterol binding protein (OSBP)-related protein (ORPs, grey) at the level of nuclear envelope
invagination (NEI) and/or endoplasmic reticulum (ER). The PH, ORD and FFAT motifs found in ORP3 are indicated. Abs used for the IS are directed against
either VAP-A or ORP3. Note the possible molecular interaction target of ICZ. (h-j) SW480 cells were incubated with DMSO alone (control) or 10 μM ICZ for
5 h, solubilized and subjected to IS using either anti-ORP3 or anti-VAP-A Ab followed by Protein G-coupled magnetic beads. The input (1/50) and entire
bound fractions were probed by immunoblotting for ORP3, VAP-A and Rab7 (h). The ratio of protein immunoreactivities of the indicated pairs was quantified
(i, j, n = 3). For all immunoblots, molecular mass markers (kDa) are indicated. The arrows point to the proteins of interest while the red arrow (f) indicates
specifically the hyperphosphorylated form of ORP3. For all graphs, the mean ± S.D. are shown. P values are indicated. N.s., not significant
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F IGURE  ICZ inhibits the localization of Rab7, but not
ORP3, in type II NEI. (a-c) SW480 cells were incubated with
DMSO (control), 10 μM ICZ or H-ICZ for 5 h prior to double
immunolabelling for VAP-A and ORP3 (a) or VAP-A and Rab7
(b). Cells were observed by CLSM. Arrowheads indicate the
presence of ORP3 or Rab7 (red) in VAP-A+ NEI (green) (a, b).
Note the absence of Rab7 in VAP-A+ NEI of ICZ-treated cells. Bar
graph shows the percentage of VAP-A+ NEI containing Rab7+
late endosomes (LE) (c). The means ± S.D. are shown. At least 20
VAP-A+ NEI were evaluated per experiment (n = 3). P values are
indicated. N.s., not significant. (d) SW480 cells co-expressing
ER-GFP and Rab7-RFP were treated with DMSO (control) or a
drug (10 μM, 5 h) as indicated, and then recorded by time-lapse
video microscopy every 20 s for a period of 5 min. Elapsed time is
indicated in the top right corner. Red and yellow arrowheads show
Rab7-RFP+ LE moving along ER-GFP+ NEI in the absence
(control) or presence of H-ICZ. Green arrowhead points to the
ER-GFP+ NEI, that is, devoid of Rab7-RFP in the presence of ICZ,
while red arrows indicate the Rab7-RFP moving along the nuclear
membrane under the same conditions. (e) SW480 cells were
treated as above prior to double immunolabelling for SUN2 and
Rab7, and filipin staining. Black and white images are presented to
better show filipin-labelled cholesterol (cyan arrowhead). Green
and red arrowheads point to SUN2 and Rab7 in NEI. For all,
single cell images are shown. Scale bars, 5 μm
endosome in the nucleoplasmic reticulum, we co-expressed in SW480 cells the Rab7-RFP fusion protein to label late endosomes
and chimeric GFP fused to the ER signal sequence of calreticulin and KDEL to label peripheral ER and nuclear envelope. Cells
were treated with drugs and monitored by live video microscopy. In control cells incubated with DMSO and those treated with
H-ICZ, fluorescent Rab7 could be detected in ER-GFP+ NEI in addition to the cytoplasm (Figure 5d). Videos revealed the
movement of Rab7-RFP+ late endosomes in both subcellular compartments (Videos S1 and S2). In contrast, no Rab7-RFP was
detected in the nucleoplasmic reticulum of ICZ-treated cells (Figure 5d, green arrowhead; Videos S3 and S4). Under these con-
ditions, the Rab7-RFP motility along the nuclear rim and in the cytoplasm was not abrogated, although its movement appeared
somehow slower (Figure 5d, arrows; Figure S5a, b; Videos S3 and S5). Quantification of Rab7+ late endosome velocity in the
cytoplasmic compartment was reduced in ICZ-treated cells compared with the native state and in the presence of H-ICZ (Figure
S5c), which is consistent with previous studies (Lebrand et al., 2002; Loubery et al., 2008). Similar data were obtained with
Rab7-RFP+VAP-A-GFP+ FEMX-I cells showing that the impact of ICZ on the entry and/or retention of late endosomes into the
NEI is not limited to a single cell type (Figure S5d; Videos S6-S8).
To ascertain that Rab7 labelled late endosomes rather than being uncoupled from the endosomal system, we evaluatedwhether
any organelles, notably those enriched in membrane cholesterol, were found in nucleoplasmic reticulum by employing filipin, a
naturally fluorescent polyene antibiotic that selectively binds to unesterified cholesterol in biological membranes (Kinsky, 1970).
Drug-treated cells were immunolabelled for both SUN2 and Rab7 prior to filipin staining. A strong filipin signal, often over-
lapping with Rab7, was detected in SUN2+ NEI in control cells and those treated with H-ICZ (Figure 5e). In contrast, both
filipin and Rab7 signals were excluded from NEI in ICZ-treated cells, suggesting that cholesterol-containing organelles such as
Rab7+ late endosomes were absent therein (Figure 5e). In agreement with earlier reports (Burgett et al., 2011; Liu et al., 2014), we
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observed a dramatic decrease in filipin-stained cholesterol in the plasma membrane after ICZ, but not H-ICZ, treatment (Figure
S6a). The majority of the plasma membrane cholesterol seemed to be trapped in intracellular compartments reminiscent of late
endosomes and lysosomes (Liu et al., 2014; Xu et al., 2010) (Figure S6a). These experiments suggest that ICZ impedes the sub-
cellular localization of late endosomes in the nucleoplasmic reticulum, which may explain its negative impact on EV-mediated
cell transformation.
. ICZ-mediated VOR complex inhibition is independent of cholesterol trafficking
To dissect the mechanism of inhibition of the VOR complex by ICZ, we studied the effect of compounds known to interfere with
cholesterol distribution on the integrity of the VOR complex. For instance, an accumulation of cholesterol in late endosomes
might interfere with VOR complex formation and hence with the translocation of late endosomes into nucleoplasmic reticulum.
First, we exposed SW480 cells to the FDA-approved antidepressant drug imipramine, a cationic hydrophobic amine that
induces a cholesterol accumulation in late endosomes and lysosomes (Roff et al., 1991; Wichit et al., 2017; Xu et al., 2010).
After exposure for 5 h to 100 μM imipramine, a non-toxic dose that induces intracellular cholesterol accumulation (Wichit
et al., 2017), cells were solubilized and ORP3 immunoisolated. Immunoblotting for ORP3, VAP-A and Rab7 revealed that
imipramine did not affect their expression and interactions (Figure 6a, b), suggesting indirectly that the activity of ICZ on
the VOR complex is not directly mediated by its effect on cholesterol trafficking. In contrast, an ORPphilin molecule, OSW-1,
known to competitively inhibit 25-HC binding to OSBP and ORP4L (Burgett et al., 2011), partially impeded the interaction of
Rab7 with VAP-A/ORP3 (Figure 6a, b). The latter data also suggest a potential role of the ORP3 ORD onORP3-Rab7 interaction
(see below).
Next, we evaluated the impact of imipramine and OSW-1 on the presence of Rab7+ late endosomes in nucleoplasmic retic-
ulum and the general distribution of membrane cholesterol. As described above, drug-treated cells were SUN2 and Rab7-
immunolabelled prior to filipin staining. In agreement with the co-immunoisolation data, imipramine did not prevent the entry
of Rab7+ late endosomes into SUN2+ NEI (Figure 6c). Although less drastic than with ICZ, the accumulation of membrane
cholesterol in the late Rab7+ endosomes were observed (Figure 6d). In contrast, OSW-1 partially inhibited the entry/presence
of Rab7+ late endosomes in NEI consistent with the co-immunoisolation data (Figure 6c). Analysis of lysosomal-associated
membrane protein (LAMP)-3 (CD63) and early endosome antigen 1 (EEA1) as markers of late and early endosomes, respectively
(Escola et al., 1998; Metzelaar et al., 1991; Stenmark et al., 1996), revealed the same trend for CD63 as for Rab7, whereas EEA1 is
excluded from theNEI (Figure S7a, b). The latter observation is consistent with the absence of Rab5 in theNEI (Rappa et al., 2017;
Santos et al., 2018). The cholesterol accumulation in late endosomes appears to be a rare event in OSW-1-treated cells (Figure 6d).
Thus, the accumulation of cholesterol in late endosomes as observed in imipramine-treated cells is not the primary cause of their
absence in the nucleoplasmic reticulum. The same could be true for the ICZ.
Can ICZ-induced disruption of the VOR complex and the inhibition of late endosome localization in NEI be rescued? Thap-
sigargin, known to increase cytosolic calcium and activate calcium-dependent proteins required for the normal function of the
endocytic pathway (Booth & Koch, 1989; Lloyd-Evans et al., 2008), reportedly rescued the effects of ICZ on cholesterol distri-
bution (Xu et al., 2010). The pre-treatment with thapsigargin (1 μM) for 1 h prior to ICZ incubation rescued only partially the
interaction of Rab7 with VAP-A/ORP3 (Figure 6e, f). Thapsigargin alone did not affect the VOR complex protein interactions
(Figure 6a, b, e, f). Therefore, Rab7+ late endosomes were found in the SUN2+ NEI of only a fraction of the cell population
(Figure 6g, h) suggesting that, consistent with the imipramine data, the direct effect of ICZ on the VOR complex is not directly
related to the general membrane trafficking of cholesterol.
. Computer modelling and synthesis of a novel VOR complex inhibitor
ICZ, a traditional triazole antifungal drug, has been reported to inhibit enterovirus and hepatitis C virus replication by targeting
OSBP and its homologue ORP4, indicating various molecular targets. Since our goal was to design specific compounds able
to inhibit the VOR complex and consequently the nuclear transfer of EV components, we simulated the interaction of ICZ
with ORP3 ORD (Figure 7a). We used a homology model of ORP3 based on crystallographic data recently reported for
cholesterol-bound OSBP-related protein 1 (ORP1) complex (see Materials and Methods) (Dong et al., 2019). The computed
complex between the modelled ORP3 ORD and the cis (2R, 4S, 2′R)-stereoisomer of ICZ is presented, focusing on its 4-phenyl-
2-butan-2-yl-1,2,4-triazol-3-one portion, that is, inserted into the deepest region of the cavity, while the 2,4-dichlorophenyl-2-
(1,2,4-triazol-1-ylmethyl)-1,3-dioxolane substructure remains outside or at most on the rim of the cavity (Figure 7b, see inset
in top panel). In detail, the 1,2,4-triazol-3-one group is engaged by a reinforced H-bond between its carbonyl oxygen atom and
residue Arg558, which additionally stabilizes charge transfer interactions with the 4-phenyl ring (Figure 7b, top panel). The
1,2,4-triazol-3-one ring approaches Tyr593 as well, which elicits both H-bonds plus π−π stacking interactions. Furthermore, the
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4-phenyl ring is engaged in a π−π stacking with Trp653, while the 2-alkyl chain stabilizes hydrophobic contacts with Leu559.
By contrast, the 2,4-dichlorophenyl-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolane portion is seen to elicit a markedly more limited
number of interactions. Rationalizing the described interactions, the key contacts appear to be those involving the 4-phenyl-2-
butan-2-yl-1,2,4-triazol-3-one portion with the deepest residues, such as Arg558, Tyr593 and Trp653, while the remaining part of
the molecule is involved in rather weak hydrophobic bonds, especially considering that the potential polar contacts stabilized
by the most external moieties (such as those involving Arg698) should be partly shielded by the surrounding solvent molecules.
On these grounds, the differences of activity between the ICZ stereoisomers (Bauer et al., 2018) could be mostly ascribed to the
greater steric hindrance of the trans stereoisomers, which would prevent a proper insertion of the 4-phenyl-2-butan-2-yl-1,2,4-
triazol-3-one system within the deepest cavity region rather than different interactions stabilized by the 2,4-dichlorophenyl-
2-(1,2,4-triazol-1-yl-methyl)-1,3-dioxolane portion on the cavity rim. The pivotal role of these is indirectly confirmed by the
inactivity of H-ICZ. Among the 10 generated poses, only in one case was H-ICZ able to insert 4-phenyl-2-butan-2-yl-1,2,4-
triazol-3-one into the deepest region of the ORP3 cavity; however, it was unable to assume the optimal arrangement as ICZ
(Figure 7b, top panel), but rather a more superficial arrangement, missing the key contacts with Arg558, Tyr593, and Trp653 (data
not shown).
Based on the computed data, we synthesized a series of related compounds smaller than the lead ICZ with fewer functional
groups, notablymissing the dioxolan region that carries a dichlorophenyl ring and the triazolemoiety, thus reducing the possibil-
ity of side effects unrelated to the VOR complex inhibition (Figure 7a). Among them, PRR851, that bears the same 2-butanyl side
chain bound to the nitrogen in position 2 of the triazolone ring of ICZ, was assessed, while PRR846, the related unsubstituted
derivative at the same position devoid of side chain, was used as a potential negative control (Figure 7a). The key role of the above-
mentioned residues was confirmed by the docking results for the two proposed derivatives. The lack of the alkyl chain prevented
the proper arrangement of PRR846, which in all generated views appeared unable to stabilize the key contacts with Arg558, Tyr593
and Trp653 (Figure 7b). Thus, PRR846 assumed a deeper position compared to the corresponding ICZ portion by which the tri-
azole ring contacts Glu562 while missing the key interactions. In sharp contrast, both PRR851 enantiomers appeared comparable
with the corresponding ICZ moiety. In the figure 6b, (R)-PRR851 is displayed, since it shows a slightly better score compared to
(S)-PRR851. It assumed a configuration very similar to that exhibited by the 4-phenyl-2-butan-2-yl-1,2,4-triazol-3-one system
of ICZ, and elicited a rather superimposable set of interactions comprising both polar and hydrophobic contacts. Moreover, the
satisfactory arrangement of (R)-PRR851 was seen with marginal differences in seven out of 10 computed poses while a greater
heterogeneity was observed for PRR846 complexes, in which the ligand assumed superficial and/or flipped arrangements, but
never assumed a convenient fit. Finally, the optimal arrangements of (R)-PRR851, PRR846 and ICZ within the ORP3 ORD are
shown simultaneously (Figure 7b, bottom panel). This confirms the superimposable configuration of (R)-PRR851 with corre-
sponding moieties of ICZ, while PRR846 showed a deeper arrangement whereby the 1,2,4-triazol-3-one ring took the place of
the alkyl chain, missing key contacts with the ORP3 residues.
. PRR interferes with the VOR complex integrity
To evaluate experimentally the impact of PRR compounds on the VOR complex, SW480 cells were treated for 5 h with 10 μM
PRR851 or PRR846, a concentration within the range of clinically attainable ICZ serum concentrations at steady-state. For com-
parison, we employed 10 μM ICZ or ketoconazole, an imidazole that acts like ICZ on the lanosterol 14α-demethylase enzyme
via the triazole moiety (Strushkevich et al., 2010) (Figure 7a). Afterward, cells were solubilized and ORP3 was immunoiso-
lated. Recovered materials were probed for ORP3, VAP-A and Rab7 by immunoblotting. The co-immunoisolation of Rab7 was
selectively altered in cells treated with PRR851, but not with PRR846 (Figure 7c). The Rab7/VAP-A ratios were similar in sam-
ples treated with PRR851 and ICZ (Figure 7d). The inhibition of the protein interactions was also observed at lower PRR851
F IGURE  Effects of cholesterol trafficking inhibitors on the VOR complex. (a, b) Detergent cell lysates prepared from SW480 cells treated for 5 h with
DMSO alone (control) or with 10 μMH-ICZ, 10 μM ICZ, 1 μM thapsigargin (Thap), 100 μM imipramine (Imip) or 50 nM OSW-1 were subjected to
immunoisolation (IS) using anti-ORP3 Ab followed by Protein G-coupled magnetic beads. The input (1/50) and entire bound fractions were probed by
immunoblotting for ORP3, VAP-A and Rab7 (a). The ratio of protein immunoreactivities of the indicated pairs was quantified (b, n = 3–6). (c, d) Cells were
incubated as in panel a prior to immunolabelling for SUN2 and Rab7 (c) or Rab7 alone (d) together with filipin staining. Cells were analysed by CLSM. Green
arrows point to NEI, while red and blue arrowheads indicate Rab7+ late endosomes and filipin-labelled cholesterol, respectively, within NEI. White asterisks
indicate the cytoplasmic accumulation of Rab7 and cholesterol, upon drug treatments. Note that late endosomes could be found or not in NEI of OSW-1-treated
cells. (e, f) Detergent cell lysates prepared from 6-h mock-treated (control) or 10 μM ICZ- or 1 μM Thap-treated SW480 cells, as well as cells pre-treated first
with 1 μMThap for 1 h followed by 10 μM ICZ for 5 h, were subjected to IS and immunoblotting as described above (a). The ratio of protein immunoreactivities
of the indicated pairs was quantified (f, n = 3). (g) SW480 cells were incubated as in panel e prior to double immunolabelling for SUN2 and Rab7 and filipin
staining. Green arrows point to NEI, while red and blue arrowheads indicate Rab7+ late endosomes and filipin-labelled cholesterol, respectively, within NEI.
(h) Bar graph showing the corresponding percentage of SUN2+ NEI containing Rab7+ late endosomes. For all immunoblots, molecular mass markers (kDa)
are indicated, and arrows point to the proteins of interest. The mean ± S.D. are shown. N.s., not significant. Scale bars, 5 (c, g) and 10 (d) μm
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F IGURE  Structure of PRR846 and PRR851 compounds and the VOR complex inhibition. (a) The structures of ICZ, ketoconazole, PRR846
(4-(4-Chlorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one) and PRR851 (2-(butan-2-yl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one) drugs are
displayed. The reactive groups in ICZ are indicated (dashed boxes). PRR846 was produced from 4-chloroaniline treated with triethyl orthoformate
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concentration (5 μM; Figure S8a, b). In contrast, ketoconazole did not influence the VAP-A/ORP3/Rab7 interactions. Similar
data were obtained when the new drugs were incubated with detergent cell lysates instead of living cells (Figure 7e, f).
To investigate whether ICZ and PRR851 acted on the highly conserved ORP3 ORD, whose hydrophobic pocket binds a single
sterol, we evaluated the potential competition of 25-HC to ICZ or PRR851-mediated VOR complex disruption.We pre-incubated
the detergent SW480 cell lysates with 25-HC at various concentrations for 30 min prior to ICZ or PRR851 treatments. Interest-
ingly, we observed that 25-HC inhibits in a dose-dependent manner the action of both drugs, suggesting that they act on ORP3
ORD (Figure 7g, h) in agreement with the OSW-1 data (Figure 6).
To visualize the effect of drugs on the transport of late endosomes to the nucleoplasmic reticulum, the distribution of Rab7
and cholesterol was investigated as described above. Similar to ICZ-treated cells, Rab7 and cholesterol were reduced in NEI of
cells exposed to PRR851 (Figure 7i). A decrease of about 30% and 40% of SUN2+ NEI harbouring Rab7+ late endosomes upon
PRR851- and ICZ-treatment, respectively, was observed (Figure 7j). Neither PRR846 nor ketoconazole affected the presence of
Rab7 or cholesterol in NEI (Figure 7i, j). Differently from ICZ-treated cells, the general redistribution of cholesterol, particularly
between endocytic organelles and the plasma membrane, was not evidenced upon PRR851- or PRR846-treatment (Figure S6b).
Consistent with an earlier study (Strating et al., 2015), amodest redistribution of cholesterol was observed in ketoconazole-treated
cells, including accumulation of Rab7+ late endosomes (Figure S6b). These data suggest that the effects observed with PRR851
were due to the disruption of the VOR complex and not on the general cholesterol distribution.
To getmore insight about theVORcomplex protein interactions, we employed three-dimensional (3D) direct stochastic optical
reconstruction microscopy (dSTORM), a single molecule super-resolution technique. The co-localization of ORP3 and Rab7
was evaluated by immunolabelling since the binding of the latter required the interaction of ORP3 and VAP-A. dSTORM data
confirmed the absence of Rab7 in NEI in cells treated with ICZ and PRR851 (Figure 8a, left panels). The 3D-rendered images
of three specific cellular regions, that is, NEI, perinuclear zone and cytoplasm, were reconstructed and a computer model was
rendered to evaluate the linear proximity between ORP3 and Rab7 (Figure 8a, right panels). In the control samples, about 35% of
the total ORP3 observed in theNEI and perinuclear zones were at a short distance (< 10 nm) fromRab7 (Figure 8b, upper graph).
In contrast, ORP3-Rab7 pairs were rarely detected in the cytoplasm, although the vastmajority ofORP3 andRab7molecules were
found there. In addition to the negative effect on the localization of Rab7 in NEI, ICZ reduced the proximity between ORP3 and
Rab7 in the perinuclear zone (Figure 8b, middle graph). A similar observation wasmade with PRR851 (Figure 8b, bottom graph).
The influence of both drugs on cytoplasmic ORP3-Rab7 pairs was marginal due to the limited amount of these interactions
outside the nuclear regions. In addition to the impact of drugs on the ORP3-Rab7 proximity, Rab7+ structures were significantly
increased in volume, especially in ICZ-treated cells, where large structures greater than 100 nm3 were observed (Figure 8c). An
accumulation of Rab7+ large endosomes/vacuoles (> 100 nm3) in pericellular zone in ICZ-treated cells (Figure 8d) and smaller
ones (> 50 nm3) in perinuclear zone in PRR851-treated cells were detected (Figure 8e). The two last observations suggest that
ICZ-mediated cholesterol accumulation in late endosomes affects partially their trafficking frompericellular to perinuclear zones,
a situation that did not occur with PRR851, in line with the filipin data. These observations are also in agreement with the reduced
velocity of late endosomes in the presence of ICZ (see above). The accumulation of late endosomes in perinuclear areas and their
absence in NEI upon PRR851 treatment suggest that the interaction between Rab7 and ORP3-VAP-A complexes occurs at the
perinuclear region en route to NEI.
To visualize the interaction of PRR compounds with ORP3–VAP-A complex, we designed a fluorescent analogue, named
PRR898, containing a 7-nitrobenzo [1,2,5] oxadiazole moiety (Figure 8f). We used a version of PRR851 with a shorter alkyl side
chain. The lack of one or two methyl groups observed in PRR850 and PRR870, respectively (Figure 8f), did not prevent their
potential interaction with the ORD domain of ORP3 (computer modelling not shown), as illustrated experimentally by the lack
of Rab7 in ORP3-driven co-immunoisolation performed on drug-treated cells or detergent lysates (data not shown). The same
p-toluenesulfonic acid, methyl carbazate and sodium methoxide in methanol (reaction i), while PRR851 was generated from the N-alkylation of PRR846 with
2-bromobutane in the presence of sodium carbonate and 18-crown-6, 2-bromobutane in DMSO (reaction ii). (b) Homology model of ORP3 ORD with the
putative drug complex as computed by docking simulations for ICZ (top panel), PRR846 and PRR851 (middle panels) within the binding cavity. A composite
image compares the simulations of each compound (ICZ, PRR846 and PRR851; bottom panel). For each complex, the primary ChemPLP score is indicated.
The inset (top panel) is focused on the deepest portion of the ORP3 cavity and depicts the arrangement of the ICZ moieties around the cavity in the inlet. (c, d)
SW480 cells were incubated with DMSO (control), 10 μM ICZ, PRR851, PRR846 or ketoconazole for 5 h, solubilized and subjected to immunoisolation (IS)
using anti-ORP3 Ab followed by Protein G-coupled magnetic beads. The input (1/50, for Rab7 only) and entire bound fractions were probed by
immunoblotting for ORP3, VAP-A and Rab7 (c). The ratio of protein immunoreactivities of the indicated pairs was quantified (d, n = 3). (e-h) Detergent
SW480 cell lysates were incubated with DMSO (control), 10 μM ICZ, PRR851, PRR846 or ketoconazole for 30 min on ice (e), and then subjected to IS and
immunoblotting as described above. Alternatively, lysates were pre-incubated with 25-HC at the indicated concentration for 30 min prior to drug treatments
(g). As internal controls, cell lysates were treated for 1 h with DMSO (control), 10 μM ICZ, 10 μM PRR851 or 100 μM 25-HC. The ratio of protein
immunoreactivities of the indicated pairs was quantified (f, h, n = 3). The molecular mass markers (kDa) are indicated, and arrows point to the proteins of
interest (c, e, g). (i, j) SW480 cells were incubated with DMSO (control), 10 μM ICZ, PRR851, PRR846 or ketoconazole for 5 h prior to double immunolabelling
for Rab7 and SUN2 and staining with filipin. Cells were analysed by CLSM (i). Arrow indicates SUN2+ NEI (green) and arrowheads point to Rab7 (red) and
filipin-labelled cholesterol (cyan) therein. Bar graph shows the percentage of SUN2+ NEI containing Rab7+ late endosomes (LE) (j). The mean ± S.D. are
shown. P values are indicated. N.s., not significant. Scale bars, 5 μm
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F IGURE  Impact of ICZ and PRR851 on the proximity of ORP3 and Rab7 in various subcellular zones. (a-e) SW480 cells were treated with 10 μM ICZ or
PRR851 or with the DMSO (control) for 5 h, fixed and the subcellular localization of ORP3 (green) and Rab7 (red) was analysed by immunolabelling using 3D
dSTORM as described under ‘Materials and Methods’. Whole cell images (a, left panels) and magnified areas (white boxes) of NEI, perinuclear and cytoplasm
(a, right panels) are displayed. Corresponding Imaris-based, 3D-rendered images were reconstructed and a computer model was rendered to show the relative
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observation was made with fluorescent PRR898 indicating that it inhibits the binding of Rab7 to ORP3/VAP-A complex. SW480
cells expressing ER-RFP were then incubated with PRR898 (2 μM) for 1 h and observed immediately or after 30, 60, 120, 180 and
240min of chase by CLSM (Figure 8g). In the first 60min, PRR898 appeared as a weak and discrete signal distributed throughout
the cytoplasm (Figure 8h); bright signals began to develop particularly in the perinuclear zone, especially at the entrance of the
NEI, as observed after 180 min, suggesting an accumulation of the drug where ORP3–VAP-A complexes possibly occur.
. PRR inhibits pro-metastatic morphological transformation
We evaluated whether PRR851, like ICZ, could inhibit EV-mediated cell morphological transformation as well as cell motility.
SW480 cells were pre-treated with 10 μM PRR851 or PRR846 as well as ICZ as a positive control for 10 min prior to incubation
for 5 h with EVs (1 × 109 particles/ml) derived from SW620 cells. Morphological alterations were then assessed after cell fixation
and immunolabelling of CD9 to visualize the plasma membrane and its blebs (Figure 9a). The number of rounded cells or those
with membrane blebs were significantly lower in PRR851- and ICZ-treated cells compared to mock-treated cells exposed to EVs
(Figure 9a). Similar to the controls, no effect was observed with PRR846, suggesting that this chemical drug did not prevent the
EV-mediated cell morphological transformation (Figure 9a). Similar data were obtained when 2 × 109 particles/ml were used
(Figure S9). In the latter case, doubling the amount of EVs increased the proportion of rounded recipient cells and their bleeding.
To complement these experiments, we assessed cell motility. To this end, a scratch wound healing assay was performed where
SW480 cells were treated with drugs (ICZ or PRR851) in the absence or presence of SW620 cell-derived EVs for 5 h. Remarkably,
both drugs reduced the recovery of wound areas, that is, stimulated by EVs (Figure 9b).
These data prompted us to visualize the impact of drugs on endocytosis and nuclear transfer of EV components using CD9-
GFP+ EVs as described above. After 5 h of incubation of CD9-GFP+ EVswith drug-treated cells, none of the chemicals interfered
with EV endocytosis, as shown by the intensity of CD9-GFP cytoplasmic signals (Figure 9c). Similar data were obtained using
membrane dye-labelled EVs and flow cytometry analysis (data not shown). In contrast, the nuclear transfer of CD9-GFP was
significantly reduced in PRR851-treated cells as reported above for ICZ, but not in cells treated with PRR846 or ketoconazole
(Figure 9d; Figure S3d). Quantification of three independent experiments revealed that nuclear GFP in PRR851-treated cells was
reduced to 4.1 ± 0.9 (mean ± S.D.) punctate signals per nucleus similar to ICZ-treated cells, that is, 4.6 ± 0.4, while control cells
and PRR846- or ketoconazole-treated cells had values of 19.9± 2.2, 18.1± 1.7 and 18.5± 1.0, respectively. The difference between
PRR851- or ICZ-treated cells and control cells was statistically significant (P values of 0.005 and 0.01, respectively). Altogether,
these data suggest that the impact of drugs on morphology and migration of colon cancer cells depends on the integrity of the
VOR complex and consequently on the nuclear transfer of EV cargo.
. Toxicity of ICZ and PRR
Finally, the cytotoxicity of the drugswas evaluated using colorimetric assay (MTS reagent) as described inMaterials andMethods.
Cell growth was assessed every 24 h for a total of 72 h. SW480 and FEMX-I cells were used as well as primary human MSCs
and fibroblasts, the latter often being the first targets for EVs derived from cancer cells in the tumour microenvironment. ICZ,
regardless of its concentrations, had little effect on the growth of SW480 cells, whereas H-ICZ caused a dose-dependent delay in
cell growth (Figure S10a). After 72 h of incubation, 10μMICZandH-ICZ significantly reduced the number ofmetabolically active
FEMX-I cells (Figure S10b). Both drugs appeared to reduce the growth ofMSCs, especially at higher concentrations (Figure S10c).
In contrast, only H-ICZ had an inhibitory effect on fibroblasts (Figure S10d). We then investigated the effects of PRR compounds
and ketoconazole (Figure S10e, f). At 10 μM, PRR851 and PRR846 exposure had little effect on cancer cells and MSCs over 72 h.
Thus, their effect on cell growth was milder than ICZ, particularly on primary cells. Ketoconazole had no effect on cancer cells
but reduced the growth of MSC similarly to ICZ.
structure and distance between ORP3 and Rab7 with the heat map indicating their linear proximity (blue to green: 0 to 50 nm) (a). The distance between the
total ORP3 molecules and Rab7 in each subcellular area was scored as inferior or superior to 10 nm and data plotted as percentage of total ORP3 in each cell
(n = 10 independent cells from three distinct experiments) (b). 3D-rendered images from pericellular zone as indicated in panel a (yellow box) were
reconstructed to illustrate the difference in volume of Rab7+ structures of control compared with ICZ- and PRR851-treated cells (c). The volume of Rab7+
structures greater than 20 nm3 in the pericellular and perinuclear zones is depicted (n = 20 independent cells were analysed per condition) (c). The numbers of
Rab7+ structures with a volume greater than 100 or 50 nm3 in the pericellular and perinuclear zone, respectively, of a given cell are graphed (n = 20 cells) (d, e).
(f) Chemical structures of PRR analogues including the fluorescent compound PRR898. (g) Methodology of the PRR898 experiments. (h) SW480 cells
expressing ER-RFP (red) were exposed to 2 μM PRR898 (green) for 1 h, washed and incubated for the indicated time prior to CLSM analysis. Note the
progressive accumulation of PRR898 in the perinuclear zone as indicated by an increase in fluorescence intensity (green arrow). The asterisk indicates the
fluorescence of PRR898 outside the cell after 1-h incubation, while the red arrowhead indicates PRR898 inside the NEI. The mean ± S.D. and P values are
presented. Scale bars, 5 μm (a, left panels; h), 500 nm (a, right panels; c, top and middle panels), 400 nm (c, bottom panel)
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F IGURE  PRR851 inhibits EV-induced
pro-metastatic morphological transformation and nuclear
transfer of EV cargo in SW480 cells. (a) SW480 cells were
pre-treated with DMSO (control), 10 μM ICZ, PRR851 or
PRR846 for 10 min prior to incubation without or with
EVs (1 × 109 particles/ml) derived from SW620 cells for
5 h prior to CD9 immunolabelling. Cell morphology was
analysed by CLSM. Bar graphs show the percentage of
cells harbouring a rounded (left) or blebbed (right)
morphology upon exposure to EVs. The mean ± S.D. are
shown. At least 50 cells were evaluated per condition and
independent experiment (n = 6). (b) Representative
images of the scratch wound healing assay of SW480 cells
treated with 10 μM drugs (ICZ, PRR851) without or with
EVs (7.5 × 108 particles/ml) derived from SW620 cells for
5 h (upper panels). The percentage of the remaining
wound area was assessed as described in Materials and
Methods. The mean ± S.E.M. (n = 2 independent
experiments) is presented (lower panel). (c, d) SW480
cells were pre-treated for 10 min with DMSO (control), 10
μM ICZ, PRR851, PRR846 or ketoconazole prior to 5-h
incubation with FEMX-I cell-derived CD9-GFP+ EVs in
the absence or presence of drugs. Cells were then fixed
and immunolabelled for SUN2. The amounts of
EV-derived CD9-GFP in the cytoplasmic (c) and nuclear
(d) compartments were analysed by CLSM and quantified.
Mean with the range of green fluorescence per slice from
10 individual representative cells are displayed as well as
composites of 21 optical x-y sections (c, inset). Nuclear
CD9-GFP was evaluated from 50 cells per condition and a
representative experiment with mean ± S.D. is shown (d).
P values are indicated. N.s., not significant. Scale bars,
5 μm
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 DISCUSSION
By studying EV-cell communication using biochemical, loss-of-function and high-resolution microscopy techniques, we have
demonstrated that FDA-approved ICZ and a novel small compound PRR851 interfere with EV-mediated pro-metastaticmorpho-
logical transformation andmigration behaviour of cancer cells by acting as inhibitors of nuclear transfer of late endosome-carried
EV cargo. Silencing ORP3 or VAP-A has been shown to block the nuclear transfer of EV cargo inmelanoma andHeLa cells (San-
tos et al., 2018) as well as cell transformation of colon cancer cells (this study). Both drugs can recapitulate these cellular effects.
Along with these inhibitions, they interfered with the integrity of the VOR complex and the entry of late endosomes into the
nucleoplasmic reticulum, suggesting that the latter are responsible for the above-mentioned effects. Knowing that cancer cells
hijack their surrounding microenvironment and that EVs derived from them determine the pre-metastatic niche, inhibitors of
nuclear transfer of EV cargo into host cells could find cancer therapeutic application, notably in combinationwith direct targeting
of cancer cells. Our data on SW480 cell transformation by SW620 cell-derived EVs and its inhibition by ICZ/PRR851 illustrate
this potential use.
Repurposing of the antifungal agent ICZ for cancer has been based on the identification of several potential cancer targets,
including the Hedgehog and the mTOR pathways (Head et al., 2015; Kim et al., 2010), but not on its action on proteins of the
OSBP family. Compared to ICZ, PRR851 has many advantages and fewer negative effects on cell growth or other cellular events,
making it an important breakthrough in the search for an inhibitor of intercellular communication. For instance, the molar
concentrations of ICZ and PRR851 required for inhibition of the VOR complex were similar; however, due to the ∼3-fold lower
molecular weight of PRR851, the absolute amount of drug required to achieve the same effect was considerably less. The lack
of moieties that inhibit other non VOR complex-related cellular targets, suggests that PRR851 should have a clinically more
favourable toxicity profile, which is consistent with MTS assay. Moreover, PRR851 has only one chiral centre (in contrast to three
in ICZ), which is present a simpler situation, both in terms of stereoselective synthesis and potency of the two stereoisomers.
Importantly, molecular docking indicated that both possible stereoisomers have similar positioning in the ORD pocket.
The scheme utilized for the synthesis of PRR851 can be easily modified to incorporate side chains of variable lengths as illus-
trated with PRR850, PRR870 and fluorescent PRR898 analogues. The latter aspect is interesting since its structure can be adapted
to interfere with the function of other OSBP-related proteins, where subtle conformational changes can be observed in the
hydrophobic pockets of their ORD domain (Olkkonen, 2015). The sequence and modelling analyses of ORD domain of vari-
ous ORP proteins (i.e., OSBP, ORP1, ORP2, ORP4, ORP6, ORP7 and ORP9) including the key residues Arg558, Tyr593 and Trp653
that play an essential role in stabilizing the ORP3–PRR851 complex, suggest that the key triad is present and/or in a configura-
tion accessible to PRR851 inhibition only in ORP7 in addition to ORP3 (Figure S11a; data not shown). This may also explain the
apparently limited toxicity of PRR851. The potential impact of PRR851 to other OSBP-related proteins, notably ORP7, needs to
be investigated as well as their subcellular localization. Until now, only ORP3, but not OSBP and ORP1L, was reported in the NEI
(Santos et al., 2018).
The absence ofmajor in vivo effects on the cellular redistribution of cholesterol and on the translocation of late endosomes from
the cytoplasmic to the perinuclear zone by PRR851, in comparison to ICZ, are important issues as is the lack of antifungal activity,
since the main targets, besides cancer cells, are physiologically normal cells such as MSCs, which can be transformed by cancer
EVs. The imipramine data suggest that the cholesterol accumulation in the endosomal compartment and/or lysosomes per se as
observed after the ICZ treatment is not necessarily the main cause of VOR complex disruption. The latter is also supported by
in vitro data performed with detergent cell lysates. Nonetheless, it remains to be determined whether PRR851 could bind, albeit
in a milder manner, to the sterol-sensing domain of regulatory sterol-carrier proteins, or regulate their expression, as has been
shown for ICZ (Liu et al., 2014; Trinh et al., 2017). The next step will be to determine the molecular motors and effectors allowing
the translocation of late endosomes into NEI, a step that appears to be dependent of a microtubule network (Santos et al., 2018).
Therein, a Rab7 effector such as Rab7-interacting lysosomal protein may play a role in the regulation of late endocytic traffic
as reported in the cytoplasmic compartment (Cantalupo et al., 2001). The accumulation of enlarged Rab7+ structures in the
vicinity of the nuclear membrane in cells treated with PRR851 or at the cellular periphery of those treated with ICZ suggests
that the movement of late endosomes (or effector regulating it) in the NEI and cytoplasm may be distinct. For the moment, it
cannot be excluded that a certain threshold of cholesterol content within the membrane of the late endosome influences their
translocation (Olkkonen, 2015; Rocha et al., 2009). An involvement of the components of the nuclear pores that could facilitate
the docking of the late endosomes with the nuclear membrane is not excluded. The accumulation of fluorescent PRR analogue
at the perinuclear zone, especially at the entrance of the NEI is consistent with it. Finally, it should be mentioned that only the
phosphorylated form of ORP3 seems to be involved in VAP-A/Rab7 interactions. Mechanically, the binding of ICZ/PRR851 to
the ORD domain of phosphorylated ORP3, which is engaged in a VAP-A interaction notably at perinuclear zones, could lead to
an ORP3 conformational change that would impede the recognition of Rab7 and late endosomal membrane (Figure S11b). Inter-
relationships of the functional domains of ORP3 in membrane targeting have been demonstrated (Lehto et al., 2005; Olkkonen,
2015; Weber-Boyvat et al., 2015).
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In conclusion, we described that disruption of the VOR complex with chemical compounds interfered with the transport
of EV cargo into the nuclear compartment, resulting in the inhibition of the pro-metastatic morphological transformation of
cancer cells and their migratory properties. Applications in the field of cancer, and possibly in virology, where late endosomal
compartments are involved, could be developed.
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